FAM
SRPT icon

Fulcrum Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Fulcrum Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.31K Buy
+488
New +$9.23K ﹤0.01% 694

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Fulcrum Asset Management's SRPT Position: Q2 2026 in Review

Fulcrum Asset Management opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 488 shares worth $8.31K. The stake represents ﹤0.01% of the portfolio and ranks #694 among its holdings.

323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Fulcrum Asset Management held 488 shares of Sarepta Therapeutics worth $8.31K as of Q2 2026.
  • Sarepta Therapeutics was a new Fulcrum Asset Management position in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Fulcrum Asset Management's portfolio in Q2 2026, its #694 holding.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Fulcrum Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.